HCV screening to enable early treatment of hepatitis C: A mathematical model to analyse costs and outcomes in two populations

Current Pharmaceutical Design

Volumn 14, Issue 17, 2008, Pages 1655-1660

  Tramarin, Andrea ^a   Gennaro, N ^a   Compostella, F A ^c   Gallo, C ^a   Wendelaar Bonga, L J ^b   Postma, M J ^b  

^a Agenzia Regionale Socio Sanitaria del Veneto   (Italy)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c NONE

Author keywords

Cost effectiveness analysis; Hepatitis C virus; Screening HCV

Indexed keywords

PEGINTERFERON;

ACUTE HEPATITIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; INTRAVENOUS DRUG ABUSE; ITALY; MASS SCREENING; MATHEMATICAL MODEL; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; REVIEW; SURGICAL PATIENT;

COHORT STUDIES; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HEALTH CARE COSTS; HEPATITIS C; HUMANS; MARKOV CHAINS; MASS SCREENING; MODELS, THEORETICAL; POSTOPERATIVE COMPLICATIONS; QUALITY-ADJUSTED LIFE YEARS; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME;

EID: 47349111904     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208784746833     Document Type: Review

References (36)

1. EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999; 341: 556-62.
2. Alter MJ, Kuhnert WL, Finelli L. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomin Rep 2003; 52(RR-3):1-13, 15.
3. Anonymous. National Institute of Health Consensus Development Conference Panel: Management of hepatitis C. Hepatology 1997; 26 (Suppl): 2-105.
4. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic, hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-32.
5. Castells L, Vargas V, Gonzalez A, Esteban J, Esteban R, Guardia J. Long interval between HCV infection and development of hepatocellular carcinoma. Liver 1995; 15: 159-63.
6. Blackard JT, Shata MT, Shire NJ, Sherman KE. Acute hepatitis C virus infection: A chronic problem. Hepatology 2008; 47: 321-31.
7. Seeff LB. Natural history of hepatitis C. Am J Med 1999; 107(6B): 10S-5S.
8. Jaeckel E, Comberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel K et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345: 1452-7.
9. Licata A, Di BD, Schepis F, Shahied L, Craxi A, Camma C. When and how to treat acute hepatitis C? J Hepatol 2003; 39: 1056-62.
10. Hoey J, Wooltorton E. Early treatment of acute hepatitis C infection may lead to cure. CMAJ 2001; 105: 1527.
11. Kim WR, Poterucha JJ, Hermans JE, Therneau TM, Dickson ER, Evans RW, et al. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med 1997; 127: 866-74.
12. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 290: 228-37.
13. Santantonio T. Treatment of acute hepatitis C. Curr Pharm Des 2004; 10: 2077-80.
14. Wong JB, Bennett WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis C: Risks, benefits, and costs. JAMA 1998; 280: 2088-93.
15. Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999; 30: 1318-24.
16. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127: 855-65.
17. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996; 313: 275-83.
18. Fabris P, Baldo V, Baldovin T, Bellotto E, Rassu M, Trivello R, et al. Changing epidemiology of HCV and HBV infections in Northern Italy: A survey in the general population. J Clin Gastroenterol 2008; 42: 527-32.
19. Ministero della salute. Dipartimento della Prevenzione e della communicazione Rilevazione delle attivita nel settore tossi-codipendenze - anno 2006. [http://www-ministerosalute.it/imgs/ C17_pubblicazioni_427_allegato.Pdf].
20. Nomenclatore Tariffario Prestazioni Specialistiche Ambulatoriali. Bollettino Ufficiale Regione Veneto 2006.
21. Kondili LA, Chionne P, Costantino A, Villano U, Lo NC, Pannozzo F, et al. Infection rate and spontaneous seroreversion of anti-hepatitis C virus during the natural course of hepatitis C virus infection in the general population. Gut 2002; 50: 693-6.
22. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958-65.
23. Mele A, Spada E, Sagliocca L, Ragni P, Tosti ME, Gallo G, et al. Risk of parenterally transmitted hepatitis following exposure to surgery or other invasive procedures: Results from the hepatitis surveillance system in Italy. J Hepatol 2001; 35: 284-9.
24. Santantonio T, Sinisi E, Guastadisegni A, Casalino C, Mazzola M, Gentile A, et al. Natural course of acute hepatitis C: A long-term prospective study. Dig Liver Dis 2003; 35: 104-13.
25. Coppola RC, Masia G, Pradat P, Trepo C, Carboni O, Argiolas F, et al. Impact of hepatitis C virus infection on healthy subjects on an Italian island. J Viral Hepat 2000; 7: 130-7.
26. Bonkovsky HL, Snow KK, Malet PF, Back-Madruga C, Fontana RJ, Sterling RK et al. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol 2007; 46: 420-31.
27. Kallman J, O'Neil MM, Larive B, Boparai N, Calabrese L, Younossi ZM. Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection. Dig Dis Sci 2007; 52: 2531-9.
28. Wong JB. Hepatitis C: Cost of illness and considerations for the economic evaluation of antiviral therapies. Pharmacoeconomics 2006; 24: 661-72.
29. Loubiere S, Rotily M, Moatti JP. Prevention could be less costeffective than cure: The case of hepatitis C screening policies in France. Int J Technol Assess Health Care 2003; 19: 632-45.
30. Sheerin IG, Green FT, Sellman JD. What is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in Now Zealand? Drug Alcohol Rev 2004; 23: 261-72.
31. Leal P, Stein K, Rosenberg W. What is the cost utility of screening for hepatitis C virus (HCV) in intravenous drug users? J Med Screen 1999; 6: 124-31.
32. Singer ME, Younossi ZM. Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. Am J Med 2001; 111: 614-21.
33. Stein K, Dalziel K, Walker A, Jenkins B, Round A, Royle P. Screening for hepatitis C in genito-urinary medicine clinics: A cost utility analysis. J Hepatol 2003; 39: 814-25.
34. Frick DN, Lam AM. Understanding helicases as a means of virus control. Curr Pharm Des 2006; 12(11): 1315-38.
35. Tanikawa K. Recent advances in antiviral agents: Antiviral drug discovery for hepatitis viruses. Curr Pharm Des 2006; 12(11): 1371-7
36. Tsai CH, Lee PY, Stollar V, Li ML. Antiviral therapy targeting viral polymerase. Curr Pharm Des 2006; 12(11): 1339-55.